论文部分内容阅读
目的评价米格列奈钙对2型糖尿病(T2DM)患者尿白蛋白(Alb)及游离脂肪酸(FFA)的影响。方法 30例T2DM患者口服米格列奈钙30mg/d,分别检测治疗前、治疗后3、6、12个月的空腹血糖、餐后30-min及60-min血糖、空腹血浆胰岛素、糖化血红蛋白、尿Alb、空腹血脂、空腹及餐后60-min FFA。结果与治疗前比较,米格列奈钙治疗3、6、12个月后,空腹血糖、餐后血糖和糖化血红蛋白逐渐降低(P<0.05)。与治疗前比较,米格列奈钙治疗12个月后,尿Alb和60-minFFA明显降低[(28.80±3.31)mg/L vs.(20.67±1.39)mg/L和(0.53±0.04)mmol/L vs.(0.31±0.03)mmol/L](P<0.05)。结论米格列奈钙不仅可以有效降低血糖,而且可以降低尿Alb及改善脂代谢。
Objective To evaluate the effects of mitiglinide on urinary albumin (Alb) and free fatty acid (FFA) in type 2 diabetes mellitus (T2DM). Methods 30 patients with T2DM were treated with mitiglinide 30mg / d orally. The fasting blood glucose, fasting plasma insulin, fasting plasma insulin, glycosylated hemoglobin , Urinary Alb, fasting lipids, fasting and postprandial 60-min FFA. Results Compared with those before treatment, the fasting blood glucose, postprandial blood glucose and HbA1c decreased gradually after 3, 6 and 12 months of mitiglinide treatment (P <0.05). Urinary Alb and 60-min FFA were significantly lower after treatment with mitiglinid compared with those before treatment [(28.80 ± 3.31) mg / L vs. (20.67 ± 1.39) mg / L and (0.53 ± 0.04) mmol / / L vs. (0.31 ± 0.03) mmol / L] (P <0.05). Conclusion Mitiglinide calcium can not only effectively lower blood glucose, but also reduce urinary Alb and improve lipid metabolism.